evipedia.ai
← Back

Yohimbine for Health & Longevity

Evidence Review created on 09/25/2026 using AI4L / Opus 5.5

Also known as: Yohimbine Hydrochloride, Yohimbine HCl, Yohimbe, Yohimbe Bark Extract, Pausinystalia yohimbe, Quebrachine, Aphrodyne, Yocon

Motivation

Yohimbine (yohimbe bark extract, yohimbine hydrochloride) is a plant compound from the bark of a West African evergreen tree. It works by releasing a natural brake on the body’s fight-or-flight nerve signals, which raises alertness, blood pressure, and the release of stored fat. It is sold mainly for fat loss and for male sexual performance.

For decades, yohimbine was a prescription treatment for erection problems before newer drugs replaced it, and it remains a common ingredient in fitness and “fat-burner” products. Its popularity comes with concern: it is one of the supplements most often linked to calls to poison centers, and product labels frequently misstate how much of it a product contains.

This review examines what human studies show about the benefits of yohimbine for sexual function and fat loss, weighed against its effects on anxiety and on the heart and blood vessels. It sets out what these findings mean for health-focused adults considering yohimbine as part of a longevity-oriented routine.

Benefits - Risks - Protocol - Conclusion

This section lists expert commentary and scientific articles that give a high-level overview of yohimbine.

  • Erectile Dysfunction - Shayna Sandhaus

    Life Extension’s erectile-dysfunction protocol includes a yohimbine section covering its alpha-2 receptor (nerve-signal brake) mechanism, trials alone and with L-arginine, and side effects such as palpitations, anxiety and raised blood pressure.

  • Yohimbe and Yohimbine in Dietary Supplement Products - Operation Supplement Safety

    A US Department of Defense supplement-safety summary covering marketing claims, label inaccuracy, the limited evidence for performance and weight loss, and documented cardiovascular and psychiatric harms.

  • Yohimbine: a clinical review - Tam et al., 2001

    A comprehensive narrative review of pharmacology, erectile-function trials and tolerability. Its authors worked for NitroMed, a company developing yohimbine-based combination products, a financial interest in favorable conclusions.

Only three sources met the bar of discussing yohimbine in substantial depth. Andrew Huberman and Peter Attia mention yohimbine only in brief segments of broader podcast episodes, which is too little for a high-level overview, so those episodes are not listed. Content by Rhonda Patrick (FoundMyFitness), Chris Kresser, and Lifespan.io could not be included because on-site searches returned no yohimbine material.

Grokipedia

  • Yohimbine

    Covers chemistry, pharmacology, medical uses, adverse effects, drug interactions, weight-loss research, regulation and veterinary use in one overview, useful for orientation before reading primary studies.

Examine

  • Yohimbine

    Summarizes dosing used for fat loss (0.2 mg/kg daily, fasted), graded human outcomes, and a safety database covering side effects, drug interactions, pregnancy and label-accuracy concerns.

ConsumerLab

Systematic Reviews

These systematic reviews and meta-analyses cover yohimbine’s main claimed benefits and its principal risk, provoked anxiety and panic.

Mechanism of Action

Yohimbine is an indole alkaloid (a nitrogen-containing plant compound). Its main action is blocking alpha-2 adrenergic receptors (brake receptors that tell nerve endings to stop releasing noradrenaline, the main fight-or-flight nerve signal). Removing this brake raises noradrenaline release and increases sympathetic nervous system (fight-or-flight nerve) activity.

This single action explains most of its effects:

  • Sexual function: stronger noradrenaline signalling in spinal and brain arousal centers. A competing view attributes part of the effect to penile blood flow, and some researchers attribute much of the response to placebo.
  • Fat release: blocking alpha-2 receptors on fat cells removes a brake on lipolysis (fat breakdown), while extra noradrenaline stimulates beta-adrenergic receptors (receptors that switch fat release on). Studies in women suggest the noradrenaline route dominates (Berlan et al., 1991).
  • Blood pressure, anxiety and saliva: consequences of higher fight-or-flight output.

Key pharmacological properties:

  • Selectivity: strongest at alpha-2 receptors; weaker at alpha-1 (vessel-tightening), serotonin 5-HT1A and dopamine D2 (mood and reward) receptors.
  • Absorption and half-life: oral bioavailability (share reaching the blood) ranges 7–87%; the half-life (time for blood levels to halve) is about 0.6 hours (Guthrie et al., 1990).
  • Metabolism: mainly by CYP2D6 (a liver enzyme that breaks down many drugs) to active 11-hydroxy-yohimbine, whose half-life is about 6 hours (Le Corre et al., 1999).
  • Distribution: enters the brain readily; overall tissue distribution is low, with a volume of distribution (apparent body space the drug fills) of about 32 L (Le Corre et al., 1999).

Historical Context & Evolution

The bark of the West African yohimbe tree was used in traditional practice as an aphrodisiac and stimulant. Yohimbine was isolated in the 1890s and became one of the earliest prescription treatments for impotence, sold as yohimbine hydrochloride tablets for decades.

Several lines of research turned it into a health-optimization compound:

  • Erectile dysfunction (1980s–1990s): placebo-controlled trials and two meta-analyses found modest benefit (Ernst & Pittler, 1998). After phosphodiesterase-5 inhibitors (prescription erection drugs such as sildenafil) arrived in 1998, clinical use declined, driven by more effective alternatives rather than by new negative data on yohimbine.
  • Psychiatric research (1980s onward): Yale researchers used yohimbine to provoke anxiety and panic, revealing heightened noradrenaline sensitivity in panic disorder and post-traumatic stress disorder (Charney et al., 1987). This later inspired trials pairing it with exposure therapy (structured confrontation with feared situations).
  • Fat release (1988–1991): Toulouse pharmacologists showed that oral yohimbine raises blood fat levels in fasting people (Galitzky et al., 1988), an idea fitness culture adopted as a “stubborn fat” strategy.
  • Safety era (2000s–2010s): poison-center reports and product analyses documented rising adverse events and inaccurate labels (Kearney et al., 2010; Cohen et al., 2016). The European Union prohibited yohimbe bark in foods in 2019, while the US still permits yohimbine supplements.

Current standing remains mixed: a modest, replicated erectile benefit; small, unreplicated fat-loss data; and a well-characterized stimulant risk profile.

Expected Benefits

High 🟩 🟩 🟩

Erectile Function in Men With Erectile Dysfunction

Yohimbine improves erections in men with erectile dysfunction (persistent difficulty achieving or keeping an erection), probably by strengthening arousal signals in the spinal cord and brain. Two independent meta-analyses of randomized controlled trials found consistent benefit over placebo (Ernst & Pittler, 1998; Wibowo et al., 2021). Effects are modest, most trials are small and pre-2000, and no data show gains in men with normal function.

Magnitude: Odds ratio (how many times higher the odds of improvement are with treatment than with placebo) of 3.85 across seven trials; in a 48-man trial of psychological-origin erectile dysfunction, 62% improved on 18 mg/day versus 16% on placebo (Reid et al., 1987).

Standing Blood Pressure in Autonomic Failure

In autonomic failure (disease of the nerves that automatically regulate blood pressure), yohimbine raises standing blood pressure by releasing noradrenaline from surviving nerve fibers. A randomized placebo-controlled crossover trial (each patient receiving every treatment in turn) in 31 patients found it outperformed pyridostigmine (Shibao et al., 2010), and a systematic review listed it among few agents reducing orthostatic hypotension (blood-pressure drop on standing) (Logan & Witham, 2012). In people with normal blood pressure, the same effect is unwanted.

Magnitude: Standing diastolic blood pressure rose 11 mmHg versus placebo 60 minutes after 5.4 mg, with significant relief of presyncope (near-fainting symptoms).

Medium 🟩 🟩

Fat Loss and Body Composition

Yohimbine increases fat release in the fasted state, an effect a meal abolishes (Galitzky et al., 1988). Two small randomized trials measured different endpoints: added weight loss in 20 obese women on a 1,000-kcal diet (Kucio et al., 1991) and lower body-fat percentage in 20 elite soccer players (Ostojic, 2006). Neither result has been replicated, and neither trial lasted beyond three weeks.

Magnitude: Weight loss of 3.55 kg versus 2.21 kg on placebo over 3 weeks at 20 mg/day; body fat fell from 9.3% to 7.1% over 21 days at 20 mg/day, with no change in muscle mass.

Relief of Drug-Induced Dry Mouth

Yohimbine increased saliva production in 10 depressed patients with xerostomia (dry mouth) caused by tricyclic antidepressants (an older antidepressant class) or antipsychotics (drugs for psychosis), outperforming the reference dry-mouth drug anetholtrithione in a randomized crossover trial (Bagheri et al., 1997). The effect likely reflects blockade of alpha-2 receptors that restrain salivary glands. Relevance is limited to people taking such drugs.

Magnitude: Salivary flow rose significantly more with 18 mg/day of yohimbine than with anetholtrithione after 5 days; the published abstract reports no outcome figure.

Faster Antidepressant Response

Added to the antidepressant fluoxetine, yohimbine hastened improvement in major depression, likely by boosting noradrenaline and serotonin signalling. In a randomized double-blind trial of 50 patients, response came significantly sooner than with fluoxetine plus placebo (Sanacora et al., 2004). The trial lasted only 6 weeks, yohimbine doses were adjusted to blood pressure, and the result has not been replicated.

Magnitude: 65% versus 42% of patients met response criteria on the Hamilton depression scale (a standard clinician-rated depression score) at the last visit, with responses arriving significantly faster over 6 weeks.

Low 🟩

Anxiety Treatment Augmentation ⚠️ Conflicted

Before exposure sessions, yohimbine may help patients unlearn fears. Positive trials in claustrophobia (Powers et al., 2009) and social anxiety (Smits et al., 2014) contrast with a null virtual-reality phobia trial (Meyerbröker et al., 2018), possibly because exposure format differed. Net reading: a possible modest add-on effect within supervised therapy.

Magnitude: Cohen’s d (standardized group difference; 0.5 is moderate, 0.8 large) of 1.68 for peak fear at 1-week follow-up in 24 claustrophobic adults; d = 0.53 on self-rated social anxiety but 0.09 on clinician ratings.

Insulin Secretion in ADRA2A Risk-Variant Carriers

Some people with type 2 diabetes carry an ADRA2A variant (gene for the alpha-2A receptor, which restrains insulin release) that lowers insulin secretion. In a placebo-controlled trial of 50 patients, single doses restored early insulin release in carriers only (Tang et al., 2014). Long-term glucose data are absent.

Magnitude: Early insulin secretion rose 29% in risk-variant carriers after 20 mg; the disposition index (insulin release adjusted for insulin sensitivity) improved 43%.

Uncontrolled reports suggested yohimbine reverses sexual side effects of SSRIs (selective serotonin reuptake inhibitors, common antidepressants). A placebo-controlled trial in women found none (Michelson et al., 2002), while mostly uncontrolled male anorgasmia (inability to reach orgasm) data looked positive (Gómez-Bueno et al., 2025). Net reading: controlled evidence shows no benefit.

Magnitude: No difference from placebo after 6 weeks in 35 yohimbine-treated premenopausal women on fluoxetine; orgasm improved in 55% of men with anorgasmia, only partly antidepressant-related, in pooled, mostly uncontrolled data.

Anaerobic Exercise Performance ⚠️ Conflicted

A single 2.5 mg dose raised repeated-sprint cycling power in 18 active women (Barnes et al., 2022). Three weeks of 20 mg/day left strength, jump and sprint tests unchanged in elite soccer players (Ostojic, 2006), possibly reflecting acute versus daily dosing or population. Net reading: no consistent performance benefit.

Magnitude: Acute mean power and total work were significantly higher, but the effects were small: yohimbine accounted for only 2–6% of the spread in scores; no performance test changed after 21 days of daily use.

Alertness and Cognitive Performance

Yohimbine raises subjective arousal through noradrenaline release, the basis of its marketing as a stimulant. In a 121-person placebo-controlled trial, 20 or 40 mg did not change working memory (Wanke et al., 2020). Evidence for alertness rests on self-reports.

Magnitude: No change in n-back (a standard working-memory test) performance at 20 or 40 mg; Bayes factor (ratio of evidence for an effect versus none; below 0.1 is strong evidence of no effect) of 0.086 for any yohimbine effect.

Speculative 🟨

Protection Against Liver Scarring

In rats with diet-induced fatty-liver inflammation, yohimbine reduced liver scarring, and alpha-2A receptor levels were raised in human fatty-liver scarring (Thomsen et al., 2026). The basis is animal data only.

Benefit-Modifying Factors

  • ADRA2A genotype: carriers of the ADRA2A risk variant (rs553668) show impaired insulin release that yohimbine corrects, whereas non-carriers show no insulin benefit.
  • CYP2D6 genotype: poor metabolizers (people whose genes produce little working enzyme; roughly 5–10% of European ancestry) clear yohimbine up to several hundred-fold more slowly, so a given dose delivers far more drug, amplifying both effects and side effects.
  • Fed versus fasted state and baseline insulin: fat release occurs in the fasted, low-insulin state and disappears after a meal, so users who eat before dosing gain little fat-loss effect.
  • Baseline blood pressure: people with low standing blood pressure from autonomic failure benefit from the pressure rise; those with normal or high baseline pressure gain no cardiovascular benefit.
  • Sex: fat-release responses are similar in women and men; erectile data apply only to men, and female sexual-function trials were negative (Michelson et al., 2002).
  • Pre-existing conditions: erectile benefit appears similar whether the cause is psychological or physical; people with anxiety disorders may benefit in supervised therapy settings but face higher anxiety risk.
  • Age: most trials enrolled adults under 60; older adults with autonomic failure respond well, while older adults with stiff arteries or heart disease have less room for blood-pressure rises.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Anxiety, Nervousness and Panic Attacks

Raising brain noradrenaline activity makes yohimbine a standard laboratory tool for provoking anxiety. It causes nervousness, restlessness, tremor and palpitations in a dose-dependent way, and people with panic disorder are far more sensitive (Charney et al., 1987). Over-the-counter use sharply worsened symptoms in four people with post-traumatic stress disorder (Southwick et al., 1999). Effects wear off as the drug clears.

Magnitude: Panic attacks in 37 of 68 patients with panic disorder (54%) versus 1 of 20 healthy volunteers (5%); anxiety or agitation in 33% of 238 poison-center cases (Kearney et al., 2010).

Blood Pressure and Heart Rate Increase

By increasing noradrenaline release, yohimbine raises blood pressure and heart rate. In a randomized crossover trial in 10 healthy men, 20 mg raised blood pressure more than placebo (Tank et al., 2007), and people with hypertension (high blood pressure) show a larger diastolic rise (Musso et al., 1995). Tachycardia (fast heart rate) is among the most frequent poison-center complaints (Kearney et al., 2010).

Magnitude: Blood pressure rose 13/8 mmHg with 20 mg versus 6/3 mmHg with placebo, and heart rate rose 5 beats/min; tachycardia occurred in 43% and hypertension in 25% of 238 poison-center cases (Kearney et al., 2010).

Medium 🟥 🟥

Gastrointestinal Distress

Nausea, vomiting, abdominal pain and diarrhea are common complaints, likely from increased nerve activity in the gut. In a review of 238 symptomatic adult exposures reported to California poison centers, gastrointestinal distress was the single most frequent effect (Kearney et al., 2010). Controlled trials at therapeutic doses report it less often, suggesting a dose-related, reversible effect.

Magnitude: Gastrointestinal distress in 46% of 238 symptomatic poison-center cases.

Severe Toxicity From Supplement Products

Poison-center yohimbine exposures more often led to severe outcomes and facility-based care than average exposures, and 98.7% involved supplement products (Kearney et al., 2010). Four people taking the same powder reached blood levels differing 22-fold, explained by CYP2D6 differences (Mueller-Schoell et al., 2021). Case reports describe repeated seizures with blood pressure of 259/107 mmHg after a massive dose (Giampreti et al., 2009) and fatal intoxications (Anderson et al., 2013).

Magnitude: Odds ratio 5.81 for a severe outcome and 2.35 for needing health-care facility management, compared with all adult exposures reported to the same poison centers.

Low 🟥

Immune-Mediated Skin and Kidney Reactions

A case report describes a generalized skin eruption, progressive kidney failure and a lupus-like syndrome (autoimmune illness mimicking lupus) after yohimbine (Sandler & Aronson, 1993). Bronchospasm (airway narrowing) has also been reported (Landis & Shore, 1989). Such reactions appear rare.

Magnitude: Not quantified in available studies. Only isolated case reports exist, so no incidence can be estimated.

Headache, Flushing, Frequent Urination and Sleep Disturbance

Heightened fight-or-flight output also causes headache, dizziness, flushing, sweating and frequent urination; late doses may disturb sleep. A Department of Defense supplement-safety summary lists headache, flushing and sweating, and a clinical review names frequent urination among the most common higher-dose effects, all reversible on stopping (Tam et al., 2001).

Magnitude: Not quantified in available studies. Safety summaries and reviews list these effects without incidence figures.

Heart-Rhythm Disturbances

Heightened fight-or-flight output can also trigger arrhythmia (irregular heart rhythm). A case report describes atrial fibrillation (chaotic rhythm of the upper heart chambers) in a healthy young man taking a yohimbine-containing bodybuilding supplement, resolving once he stopped it (Liyanage & Kodali, 2014). Sustained atrial fibrillation raises stroke risk.

Magnitude: Not quantified in available studies. Only isolated case reports exist, so no incidence can be estimated.

Heart Attack

Surges in blood pressure and heart rate can strain the heart. A federal yohimbe fact sheet links yohimbine to heart attacks, and a toxicology review lists heart attack and cardiac arrest (heart stopping) among harms of stimulant supplements including yohimbine (Corcoran, 2025). Such reactions appear rare.

Magnitude: Not quantified in available studies. Only isolated reports and class-level reviews exist, so no incidence can be estimated.

Manic Symptoms

Heightened brain noradrenaline activity may trigger manic symptoms (abnormally elevated mood and energy). Yale researchers described yohimbine-induced manic symptoms in three patients (Price et al., 1984). Such reactions appear rare, but they underlie the exclusion of people with bipolar disorder.

Magnitude: Not quantified in available studies. Only isolated case reports exist, so no incidence can be estimated.

Priapism

Priapism (a painful erection lasting hours that can damage erectile tissue) has been reported after yohimbe extract. In one case the erection resisted standard treatment and required a surgical shunt (Myers & Barrueto, 2009). Such reactions appear rare but are a medical emergency.

Magnitude: Not quantified in available studies. Only isolated case reports exist, so no incidence can be estimated.

Speculative 🟨

Direct Heart-Cell Electrical Toxicity

In human stem-cell-derived heart muscle cells, yohimbine slowed electrical firing and prolonged each electrical impulse, independent of its receptor action (Gong et al., 2022). The basis is cell-culture work only.

Risk-Modifying Factors

  • CYP2D6 genotype: clearance ranged from 25 to 15,864 mL/min across genotypes, so poor metabolizers reach far higher blood levels and toxicity at ordinary doses (Vay et al., 2020).
  • Baseline blood pressure: people with hypertension show a larger diastolic rise than people with normal pressure; uncontrolled baseline pressure raises the risk of hypertensive crisis (dangerously high blood pressure).
  • Sex: most safety data come from men; women showed no significant blood-pressure or heart-rate change at 0.2 mg/kg in fat-release studies (Berlan et al., 1991), and pregnancy-safety data are absent.
  • Pre-existing conditions: panic disorder, post-traumatic stress disorder, heart disease, arrhythmia, seizure disorders and opioid dependence markedly increase the risk of serious reactions.
  • Age: older adults more often have stiff arteries, coronary disease and multiple medications, increasing vulnerability to pressure spikes and drug interactions.
  • Body weight and dose per kilogram: fixed supplement doses deliver more drug per kilogram to lighter people, raising side-effect risk.

Key Interactions & Contraindications

  • Monoamine oxidase inhibitors (older antidepressants that block noradrenaline breakdown; phenelzine, tranylcypromine, selegiline): absolute contraindication outside specialist care; risk of severe hypertensive crisis. Autonomic-failure specialists have combined them deliberately under close monitoring (Biaggioni et al., 1994).
  • Tricyclic antidepressants (clomipramine, amitriptyline, imipramine): caution; clomipramine raised yohimbine exposure 37% in a study funded by a company developing the combination (Leutzendorff et al., 2025), likely via CYP2D6, adding blood-pressure effects. Mitigation: lower yohimbine dose with blood-pressure checks.
  • Strong CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion, quinidine): major caution; paroxetine cut yohimbine clearance more than fivefold in normal metabolizers (Vay et al., 2020), raising toxicity risk. Mitigation: avoid combination or reduce dose substantially.
  • Central alpha-2 agonists (blood-pressure drugs that damp fight-or-flight output; clonidine, guanfacine, methyldopa): avoid; direct pharmacological opposition causes loss of blood-pressure control and blunted drug effect.
  • Other antihypertensives (blood-pressure-lowering drugs; lisinopril, amlodipine, losartan): monitor; yohimbine can offset their blood-pressure lowering. Mitigation: home blood-pressure checks.
  • Beta blockers (heart and blood-pressure drugs such as propranolol, metoprolol): caution; propranolol blunts yohimbine’s fat release (Berlan et al., 1991), and leaves extra noradrenaline acting only on vessel-tightening alpha receptors, which may raise pressure. Mitigation: home blood-pressure checks.
  • Prescription stimulants (amphetamine, methylphenidate, modafinil): avoid; additive rises in heart rate, blood pressure and anxiety.
  • Phosphodiesterase-5 inhibitors (sildenafil, tadalafil): monitor; commonly combined for erectile dysfunction, with opposing blood-pressure effects and additive dizziness or palpitations. Mitigation: 2.5 mg yohimbine starting dose with standing blood-pressure checks.
  • Methadone and other opioid therapies: avoid; yohimbine provoked withdrawal symptoms and craving in methadone-maintained patients (Stine et al., 2002).
  • Over-the-counter decongestants and stimulants (pseudoephedrine, phenylephrine, caffeine tablets): caution; additive blood-pressure and heart-rate rises. Mitigation: separating use onto different days.
  • Over-the-counter CYP2D6 inhibitors (diphenhydramine): monitor; may modestly raise yohimbine levels. Mitigation: dosing yohimbine in the morning, away from nighttime antihistamine use.
  • Stimulant supplements with additive effects (caffeine, guarana, synephrine from bitter orange, rauwolscine, higenamine, ephedra): avoid stacking; additive cardiovascular strain and anxiety. Mitigation: halve both doses if combined.
  • Supplements that raise blood pressure (licorice root containing glycyrrhizin): caution; additive blood-pressure rise. Mitigation: deglycyrrhizinated licorice or home blood-pressure checks.
  • Fasting and alcohol: monitor; fasting amplifies fat release and stimulant effects; alcohol has not been formally studied with yohimbine, but both affect blood pressure and heart rhythm. Mitigation: lower doses when fasted and no use on drinking days.

Populations who should avoid Yohimbine:

  • Uncontrolled hypertension (resting blood pressure at or above 140/90 mmHg despite treatment)
  • Coronary artery disease, heart attack within the past 6 months, arrhythmia, or heart failure of NYHA (New York Heart Association, a heart-failure severity scale) class II–IV
  • Panic disorder, post-traumatic stress disorder, generalized anxiety disorder, or bipolar disorder
  • Seizure disorders
  • Pregnancy and breastfeeding
  • Liver cirrhosis Child-Pugh class B or C (liver-disease severity score) or kidney disease with eGFR below 30 mL/min/1.73 m² (estimated glomerular filtration rate, a kidney-function measure)
  • Known CYP2D6 poor metabolizers taking standard doses
  • People on methadone or buprenorphine for opioid dependence
  • Children and adolescents under 18 years

Risk Mitigation Strategies

  • Test dose with blood-pressure check: protocols start with 2.5 mg, with blood pressure and heart rate measured 60 minutes later, identifying excessive pressure or heart-rate responses before any increase.
  • Weight-based ceiling: keeping intake at or below 0.2 mg/kg daily (about 14 mg at 68 kg), the dose used without significant cardiovascular change (Berlan et al., 1991), limits hypertension and tachycardia.
  • Pharmaceutical-grade yohimbine hydrochloride: products labeled with an exact yohimbine hydrochloride amount and third-party verification reduce overdose risk from mislabeled bark extracts.
  • No stimulant stacking: not combining with caffeine, synephrine or other stimulants, or halving both doses, limits additive blood-pressure, heart-rate and anxiety effects.
  • CYP2D6 awareness: CYP2D6 genotyping and a medication review for CYP2D6 inhibitors before regular use identify people at risk of unexpectedly high blood levels and toxicity.
  • Morning dosing: dosing before early afternoon reduces sleep disruption from the approximately 6-hour active metabolite.
  • Screening for anxiety history: excluding people with panic or trauma-related symptoms outside supervised therapy prevents provoked panic attacks.
  • Home monitoring log: weekly records of blood pressure, heart rate and anxiety during the first month detect cumulative cardiovascular strain early.

Therapeutic Protocol

  • Fat-loss protocol (fitness practice): 0.2 mg/kg daily of yohimbine hydrochloride, split into 2–3 doses, taken fasted and often 15–30 minutes before training; summarized by Examine.com from Toulouse fat-release studies by Galitzky, Lafontan and Berlan (Galitzky et al., 1988).
  • Erectile dysfunction protocol (urology): 5.4 mg three times daily, or 15–30 mg daily in trials, for 6–10 weeks; championed by urologist Alvaro Morales (Queen’s University, Canada).
  • Orthostatic hypotension protocol (autonomic medicine): single 5.4 mg morning dose or before upright activity; developed by the Vanderbilt Autonomic Dysfunction Center (Italo Biaggioni, Cyndya Shibao).
  • Exposure-therapy protocol (psychiatry): 10.8 mg taken 1 hour before each exposure session, on session days only (Mark Powers, Jasper Smits).
  • Competing approaches: conventional practice uses phosphodiesterase-5 inhibitors for erectile dysfunction and midodrine or droxidopa for orthostatic hypotension; integrative and fitness practitioners use yohimbine as a low-cost add-on.
  • Starting dose: 2.5 mg, increasing by 2.5 mg every few days toward the target if blood pressure and anxiety remain acceptable.
  • Time of day: morning or before a morning workout; evening use risks sleep disruption.
  • Half-life: about 0.6 hours for yohimbine itself and about 6 hours for its active metabolite, so effects last roughly 3–6 hours.
  • Single versus split doses: daily fat-loss or erectile protocols use split doses; acute uses (exposure therapy, orthostatic symptoms) use single doses.
  • Genetic factors: CYP2D6 poor metabolizers typically need a fraction of standard doses; ADRA2A risk-variant carriers show the insulin-secretion response.
  • Sex differences: erectile protocols apply to men; women show similar fat-release responses, and dosing data for women are sparse.
  • Age: adults over 60 typically start at 2.5 mg with blood-pressure checks, given higher baseline cardiovascular risk.
  • Baseline biomarkers: resting blood pressure and heart rate set the safety margin; people starting near or above 130/80 mmHg have little room for yohimbine’s rise, while low standing pressure identifies autonomic-failure responders.
  • Pre-existing conditions: autonomic failure predicts benefit; anxiety disorders, heart disease and hypertension predict poorer tolerance.

Discontinuation & Cycling

  • Short-term or intermittent use: fat-loss protocols run for weeks, not years; exposure-therapy use is session-limited; autonomic-failure use can be long term under medical supervision.
  • Withdrawal effects: no withdrawal syndrome has been described; stopping removes effects within hours.
  • Tapering: not required pharmacologically because the drug clears within a day; no rebound effects are documented after stopping.
  • Cycling: no controlled data show tolerance or support cycling; some fitness protocols cycle 4–8 weeks on and 2–4 weeks off without supporting studies.

Sourcing and Quality

  • Form: yohimbine hydrochloride is a defined single compound; yohimbe bark extracts contain variable yohimbine plus dozens of other alkaloids, making dose unpredictable.
  • Label accuracy: in 49 US brands, yohimbine ranged from none to 12.1 mg per serving; among the 11 labels stating an amount, actual content was 23–147% of the claim (Cohen et al., 2016).
  • Third-party testing: products certified by NSF Certified for Sport, Informed Sport or USP Verified carry independent content and contaminant checks; a ConsumerLab product review found only 3 of 10 sexual-enhancement products passing its tests.
  • Undeclared drugs and overdoses: sexual-enhancement products have been recalled for undeclared prescription drugs and dangerously high undeclared yohimbine, including a September 2026 US recall.
  • Rauwolscine confusion: “alpha-yohimbine” products contain rauwolscine, a related stereoisomer (same atoms, differently arranged) with different potency; it is not interchangeable with yohimbine hydrochloride.
  • Prescription and compounded sources: yohimbine hydrochloride tablets (historically Yocon and Aphrodyne) and compounding-pharmacy capsules provide pharmaceutical-grade dosing where a prescriber is available.

Practical Considerations

  • Time to effect: fat release and blood-pressure effects begin within 30–60 minutes; erectile trials assessed benefit after 6–10 weeks of daily use; fat-loss differences appeared after 3 weeks.
  • Common pitfalls: dosing after meals (eliminating fat release), stacking with caffeine-based pre-workouts, assuming bark extracts equal yohimbine hydrochloride, and dosing by product serving rather than body weight.
  • Regulatory status (US): sold as a dietary supplement; marketing over-the-counter yohimbine to treat erectile dysfunction without US Food and Drug Administration approval is illegal, per a National Center for Complementary and Integrative Health fact sheet.
  • Regulatory status (elsewhere): the European Union prohibited yohimbe in foods in 2019; many countries restrict yohimbine to prescription. The World Anti-Doping Agency does not list it explicitly.
  • Cost and access: inexpensive and widely available as a supplement; prescription forms require a physician. Off-patent yohimbine draws few industry-funded outcome trials, unlike costly patented alternatives such as droxidopa, a structural bias in guideline evidence; payers have a financial incentive favoring the cheaper option.

Interaction with Foundational Habits

  • Sleep: indirect, potentially disrupting interaction; the active metabolite lasts about 6 hours and heightens arousal. A single 5.4 mg bedtime dose did not change sleep structure in 8 healthy men (Gentili et al., 1996), but higher or later doses remain untested; morning dosing avoids overlap.
  • Nutrition: direct, fasting-dependent interaction; food, and the insulin it triggers, abolished yohimbine’s fat release (Galitzky et al., 1988). Dosing is typically paired with fasted mornings; caffeine-containing drinks add stimulant load.
  • Exercise: potentiating interaction; fat release is reinforced during physical exercise, supporting pre-training fasted dosing. Heart rate runs higher during effort, so heart-rate zone targets shift upward.
  • Stress management: blunting interaction; yohimbine raises noradrenaline and cortisol (the main stress hormone) and is used experimentally to induce stress, working against relaxation practices and aggravating anxiety-prone states.

Monitoring Protocol & Defining Success

Baseline testing before starting covers resting and standing blood pressure, resting heart rate, a heart-rhythm tracing, fasting glucose, liver and kidney function, and anxiety and sexual-function questionnaires where relevant. CYP2D6 genotyping identifies slow metabolizers before the first dose, and a body-composition scan anchors fat-loss tracking. These results define each person’s safety margin and reference point.

Ongoing monitoring follows this cadence: home blood pressure and heart rate before and 60 minutes after the first doses, then weekly for 4 weeks, then monthly; questionnaires at 4 and 8 weeks; body composition at 8–12 weeks; liver and kidney tests every 6–12 months during long-term use. Success means the targeted benefit without sustained pressure or anxiety rises.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Resting blood pressure Below 120/80 mmHg Detects pressure rise Seated, morning, before dose and 60 minutes after; conventional high threshold 130/80 mmHg
Standing blood pressure Drop under 20/10 mmHg Detects postural drop; tracks benefit Measure after 1 and 3 minutes standing; pair with resting reading
Resting heart rate 50–70 beats/min Detects stimulant excess Conventional range 60–100 beats/min; measure on waking
ECG Normal sinus rhythm; QTc under 440 ms (men), 460 ms (women) Baseline rhythm check ECG: electrocardiogram; QTc: heart-rate-corrected QT interval (heart electrical recovery time); baseline and if palpitations occur
Fasting glucose 75–90 mg/dL Yohimbine alters insulin release Conventional normal below 100 mg/dL; 8–12 hour fast; pair with HbA1c (3-month average blood sugar)
ALT Below 25 U/L Liver clears yohimbine ALT: alanine aminotransferase, a liver-injury marker; conventional upper limit 40–55 U/L; fasting not required
eGFR Above 90 mL/min/1.73 m² Kidney injury case reports eGFR: estimated glomerular filtration rate; conventional normal above 60; pair with creatinine
CYP2D6 genotype Normal metabolizer Predicts blood levels One-time genetic test; poor and intermediate metabolizers need lower doses
Body composition (DEXA) No established target; track change from own baseline Measures fat-loss effect DEXA: dual-energy X-ray absorptiometry; same time of day and hydration state each scan
Erectile function (IIEF-5) 22–25 points Tracks sexual benefit IIEF-5: 5-item International Index of Erectile Function; conventional “no dysfunction” 22–25
Anxiety (GAD-7) 0–4 points Detects anxiety side effects GAD-7: 7-item Generalized Anxiety Disorder scale; conventional “minimal” 0–4

Qualitative markers:

  • Energy and alertness without jitteriness
  • Anxiety, restlessness or palpitations
  • Sleep onset and quality
  • Waist circumference and clothing fit
  • Erection quality and sexual satisfaction
  • Dizziness on standing

Emerging Research

  • CYP2D6 and sex differences: the completed YOKI-1 study (NCT06939608) gave a 50 µg microdose to 36 women and men grouped by CYP2D6 genotype; results, not yet posted, could define genotype- and sex-specific dosing, building on Vay et al., 2020.
  • Genotype-guided diabetes treatment: a completed phase 2 trial of 50 patients (NCT01593215) showed insulin-secretion gains in ADRA2A risk carriers (Tang et al., 2014); no longer trial has tested HbA1c or complications, which could strengthen or weaken the case.
  • Liver scarring and portal pressure: in rodents, a selective alpha-2A blocker lowered portal pressure (pressure in the liver’s main vein) and yohimbine reduced liver scarring; authors propose human trials (Thomsen et al., 2026).
  • Combination for premature ejaculation: a 15-man interaction study, funded and co-authored by a company developing the combination, found 37% higher yohimbine exposure alongside clomipramine with good tolerability (Leutzendorff et al., 2025).
  • Exposure-therapy augmentation (weakening signal): after positive pilots, a 56-person specific-phobia trial found no advantage (Meyerbröker et al., 2018); the 26-man post-traumatic stress disorder pilot (NCT01031979; Tuerk et al., 2018) remains unreplicated at scale.
  • Rapid antidepressant hypothesis: a phase 2 US National Institutes of Health trial of 11 patients (NCT00078715) tested intravenous yohimbine during sleep to mimic the next-day mood lift of sleep deprivation; results are posted, but no larger trial has followed.
  • Ongoing trials and longevity gap: current registered trials use yohimbine mainly as a stress-inducing research tool, such as a planned 20-person phase 2 opioid-use-disorder study (NCT04231708); no lifespan study in any organism or trial with cardiovascular or mortality endpoints was identified.

Conclusion

Yohimbine is a bark-derived stimulant that removes a natural brake on the body’s fight-or-flight signals. For health-focused adults, that single action produces both its uses and its drawbacks.

The strongest human evidence concerns erections: repeated controlled studies in men with erection problems show a real but modest improvement, smaller than that of modern prescription erection drugs. Good evidence also supports raising standing blood pressure in people whose automatic blood-pressure nerves have failed, an effect that becomes unwanted in people with normal or high blood pressure. Fat-loss evidence is thin, resting on a few small, short studies, and the effect depends on taking it without food. Limited evidence also suggests it speeds mood improvement when added to an antidepressant. Support for sharper thinking, sports performance, fear-focused therapy and relief of antidepressant sexual side effects is weak or mixed.

The risks are well documented and dose-related: anxiety and panic, higher blood pressure and heart rate, and stomach upset, with serious poisonings linked mostly to supplement products. People whose genes make them break the compound down slowly can reach far higher blood levels from the same amount.

The evidence base is old, small and built on short studies. One influential supportive review and a recent drug-combination study came from companies developing yohimbine products, and supplement labels are often inaccurate. No study has examined its effect on lifespan or long-term disease risk. Its value to a longevity-minded adult therefore rests on narrow, situation-specific uses rather than on any general health benefit.

Top - Benefits - Risks - Protocol